Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma; Sintilimab; Radiotherapy; Concurrent Chemoradiotherapy; Immunonutrition Interventions: Radiation: Radiotherapy; Drug: Programmed Cell Death Protein 1 Inhibitor; Dietary Supplement: Immunonutrition support Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Cancer | Cancer & Oncology | Carcinoma | China Health | Diets | Esophagus Cancer | Hospitals | Nutrition | Research | Skin Cancer | Squamous Cell Carcinoma